Private company

CSL Limited

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons3

Australian biotechnology company

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.2 From Wikipedia, CC BY-SA 4.0

Last updated Oct 16, 2026.

Overview

1994Founded1
  • Tickeron Australian Securities Exchange1
  • Industrybiotechnology1
  • HeadquartersMelbourne1
  • Websitewww.csl.com.au
  • Legal formpublic company limited by shares1
  • Listed onAustralian Securities Exchange (CSL), Australian Securities Exchange (CSL)1

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.2

How it started

Origin and Penfold directorship

CSL was founded in 1916 as Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. Under the first director, William Penfold, CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose-built Parkville premises in the following year.

Morgan directorship

After ongoing disputes with the Department of Health and its director-general John Cumpston, Penfold resigned in 1927 and was replaced by Frederic Morgan. Soon after Morgan's appointment, CSL was drawn into a serious public health disaster when a batch of its diphtheria toxin-antitoxin was implicated in the deaths of twelve children in what became known as the Bundaberg tragedy of 1928. Although CSL's manufacturing processes were absolved, its labelling procedures were seen to be in error, leading to an enduring focus on the highest standards across the facility's production.

Antivenene research and production

In 1928, CSL also became involved in antivenene (antivenom) manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute. This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930 and its commercial release in 1931.

From Wikipedia’s article on CSL Limited, shared under CC BY-SA 4.0.2

Products and brands

  • antivenom
  • blood product
  • indicators and reagents
  • vaccine

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

  • CSL Behring (United Kingdom)

From Wikidata.1

Timeline

  1. Jun 8, 1994Went public Listed on Australian Securities Exchange1
  2. 1994Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3